CORBUS PHARMACEUTICALS HOLDI (CRBP)

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company is headquartered in Norwood, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2014-10-24. The firm is engaged in developing and commercializing therapeutics for autoimmunity, fibrosis, and cancer. Its internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. The company has developed CRB-913, a second-generation cannabinoid receptor type 1 (CB1) inverse agonist designed to treat obesity and related metabolic diseases. The CRB-913 program is in the pre-clinical-stage. The company also includes Lenabasum, which is a novel, synthetic, oral molecule that selectively activates cannabinoid receptor type 2 (CB2) for the treatment of inflammation and fibrosis. Its subsidiaries include Corbus Pharmaceuticals, Inc., Corbus International Limited and Corbus Pharmaceuticals Australia Pty Ltd.

Company Info

CORBUS PHARMACEUTICALS HOLDI

500 River Ridge Drive

Norwood MASSACHUSETTS 02062

P: 16179630103

CEO: Yuval Cohen

Employees: 33

Website: https://www.corbuspharma.com/